Inflammatory bowel disease: Dysfunction of GALT and gut bacterial flora (II)

Surgeon

Volumn 1, Issue 3, 2003, Pages 125-136

  Chandran, P ^a   Satthaporn, S ^a   Robins, A ^a   Eremin, O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Crohn's disease; Gut bacterial flora; Quorum sensing molecules and probiotics; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; CIPROFLOXACIN; LACTONE DERIVATIVE; MACROLIDE; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; VIRULENCE FACTOR;

APPENDECTOMY; BACTERIAL CELL; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; CELL PROLIFERATION; CIGARETTE SMOKING; CLINICAL STUDY; CONCENTRATION (PARAMETERS); CROHN DISEASE; DISEASE MODEL; DRUG USE; ENTERITIS; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GERMFREE ANIMAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PATHOGENICITY; REVIEW; TISSUE INJURY; ULCERATIVE COLITIS; VIRUS IDENTIFICATION;

EID: 0038208014     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(03)80091-4     Document Type: Review

References (100)

1. Merger M, Croitoru K. Infections in the immunopathogenesis of chronic inflammatory bowel disease. Semin Immunol 1998; 10: 69-78.
2. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 41-62.
3. Penny WJ, Penny E, Mayberry JF, Rhodes J. Prevalence of inflammatory bowel disease amongst Mormons in Britain and Ireland. Soc Sci Med 1985; 21: 287-90.
4. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-54.
5. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811-15.
6. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts KP et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 364-71.
7. Dasso JF, Howell MD. Neonatal appendectomy impairs mucosal immunity in rabbits. Cell Immunol 1997; 182: 29-37.
8. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 1996; 184: 707-15.
9. Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA. Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis 2002; 8: 277-86.
10. McCartney AL, Wenzhi W, Tannock GW. Molecular analysis of the composition of the bifidobacterial and lactobacillus microflora of humans. Appl Environ Microbiol 1996; 62: 4608-13.
11. Fuqua C, Winans SC, Greenberg EP. Census and consensus in bacterial ecosystems: the LuxR-LuxI family of quorum-sensing transcriptional regulators. Annu Rev Microbiol 1996; 50: 727-51.
12. Chin J, Turner B, Barchia I, Mullbacher A. Immune response to orally consumed antigens and probiotic bacteria. Immunol Cell Biol 2000; 78: 55-66.
13. Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 1974; 27: 961-79.
14. Moore WE, Holdeman LV. Special problems associated with the isolation and identification of intestinal bacteria in fecal flora studies. Am J Clin Nutr 1974; 27: 1450-55.
15. Berg RD. Mechanisms confining indigenous bacteria to the gastrointestinal tract. Am J Clin Nutr 1980; 33: 2472-84.
16. Brimnes J, Reimann J, Nissen M, Claesson M. Enteric bacterial antigens activate CD4(+) T cells from scid mice with inflammatory bowel disease. Eur J Immunol 2001; 31: 23-31.
17. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-55.
18. Weinstein PD, Schweitzer PA, Cebra-Thomas JA, Cebra JJ. Molecular genetic features reflecting the preference for isotype switching to IgA expression by Peyer's patch germinal center B cells. Int Immunol 1991; 3: 1253-63.
19. Cebra JJ, Periwal SB, Lee G, Lee F, Shroff KE. Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. Dev Immunol 1998; 6: 13-18.
20. Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun 1995; 63: 3904-13.
21. Moreau MC, Ducluzeau R, Guy-Grand D, Muller MC. Increase in the population of duodenal immunoglobulin A plasmocytes in axenic mice associated with different living or dead bacterial strains of intestinal origin. Infect Immun 1978; 21: 532-39.
22. Nealson KH, Hastings JW. Bacterial bioluminescence: its control and ecological significance. Microbiol Rev 1979; 43: 496-518.
23. Bassler BL. How bacteria talk to each other: regulation of gene expression by quorum sensing. Curr Opin Microbiol 1999; 2: 582-87.
24. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol 2001; 55: 165-99.
25. Telford G, Wheeler D, Williams P, Tomkins PT, Appleby P, Sewell H et al. The Pseudomonas aeruginosa, quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Infect Immun 1998; 66: 36-42.
26. Lewenza S, Conway B, Greenberg EP, Sokol PA. Quorum sensing in Burkholderia cepacia: identification of the LuxRI homologs CepRI. J Bacteriol 1999; 181: 748-56.
27. Riedel K, Hentzer M, Geisenberger O, Huber B, Steidle A, Wu H et al. N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology 2001; 147: 3249-62.
28. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-31.
29. Bamba T, Matsuda H, Endo M, Fujiyama Y. The pathogenic role of Bacteroides vulgatus in patients with ulcerative colitis. J Gastroenterol 1995; 30: 45-47.
30. Onderdonk AB, Franklin ML, Cisneros RL. Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun 1981; 32: 225-31.
31. Tvede M, Bondesen S, Nielsen OH, Rasmussen SN. Serum antibodies to Bacteroides species in chronic inflammatory bowel disease. Scand J Gastroenterol 1983; 18: 783-89.
32. Marshall JB. Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol 1993; 88: 989-99.
33. Shafran I, Decker JW. Bacteria and Crohn's disease. Am J Gastroenterol 2001; 96: 3222-24.
34. Hermon-Taylor J, Bull TJ, Sheridan JM, Cheng J, Stellakis ML, Sumar N. Causation of Crohn's disease by Mycobacterium avium subspecies paratuberculosis. Can J Gastroenterol 2000; 14: 521-39.
35. Dixon B. The mystery MAP. Lancet Infect Dis 2002; 2: 316.
36. Fujita H, Eishi Y, Ishige I, Saitoh K, Takizawa T, Arima T, Koike M. Quantitative analysis of bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases. J Gastroenterol 2002; 37: 509-16.
37. Sechi LA, Mura M, Tanda F, Lissia A, Solinas A, Fadda G et al. Identification of Mycobacterium avium subsp. paratuberculosis in biopsy specimens from patients with Crohn's disease identified by in situ hybridization. J Clin Microbiol 2001; 39: 4514-17.
38. Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy-approaching a cure? Dig Liver Dis 2002; 34: 29-38.
39. Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34: 22-28.
40. Shomer NH, Dangler CA, Schrenzel MD, Fox JG. Helicobacter bilis-induced inflammatory bowel disease in scid mice with defined flora. Infect Immun 1997; 65: 4858-64.
41. Cahill RJ, Foltz CJ, Fox JG, Dangler CA, Powrie F, Schauer DB. Inflammatory bowel disease: an immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect Immun 1997; 65: 3126-31.
42. Burich A, Hershberg R, Waggie K, Zeng W, Brabb T, Westrich G, Viney JL, Maggio-Price L. Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. Am J Physiol Gastrointest Liver Physiol 2001; 281: G764-78.
43. Jiang HQ, Kushnir N, Thurnheer MC, Bos NA, Cebra JJ. Monoassociation of SCID mice with Helicobacter muridarum, but not four other enterics, provokes IBD upon receipt of T cells. Gastroenterology 2002; 122: 1346-54.
44. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344: 508-10.
45. Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Jr., Poland GA, Melton LJ, 3rd. Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 104-06.
46. Ghosh S, Armitage E, Wilson D, Minor PD, Afzal MA. Detection of persistent measles virus infection in Crohn's disease: current status of experimental work. Gut 2001; 48: 748-52.
47. Madsen KL. Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med 2001; 24: 250-57.
48. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-75.
49. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550-62.
50. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674-78.
51. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-32.
52. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12: 53-56.
53. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40.
54. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol 2000; 95: 1139-46.
55. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-78.
56. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220-21.
57. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16: 909-17.
58. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-05.
59. Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb 2001; 46: 334-37.
60. Fukushima Y, Kawata Y, Hara H, Terada A, Mitsuoka T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998; 42: 39-44.
61. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-91.
62. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996; 64: 5403-05.
63. Sutas Y, Soppi E, Korhonen H, Syvaoja EL, Saxelin M, Rokka T, Isolauri E. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG-derived enzymes. J Allergy Clin Immunol 1996; 98: 216-24.
64. Sutas Y, Hurme M, Isolauri E. Down-regulation of anti-CD3 antibody-induced IL-4 production by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. Scand J Immunol 1996; 43: 687-89.
65. Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr 2001; 73: 444S-50S.
66. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107-14.
67. Bjorksten B. The intrauterine and postnatal environments. J Allergy Clin Immunol 1999; 104: 1119-27.
68. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001; 107: 129-34.
69. Christensen HR, Frokiaer H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002; 168: 171-78.
70. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-58.
71. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-58.
72. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-39.
73. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000; 289: 1560-63.
74. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 1998; 10: 45-49.
75. Levy O. Impaired innate immunity at birth: deficiency of bactericidal/permeability-increasing protein (BPI) in the neutrophils of newborns. Pediatr Res 2002; 51: 667-69.
76. Haapamaki MM, Haggblom JO, Gronroos JM, Pekkala E, Alanen K, Nevalainen TJ. Bactericidal/permeability-increasing protein in colonic mucosa in ulcerative colitis. Hepatogastroenterology 1999; 46: 2273-77.
77. Monajemi H, Meenan J, Lamping R, Obradov DO, Radema SA, Trown PW et al. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology 1996; 110: 733-39.
78. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42: 477-84.
79. Shanahan F. Nutrient tasting and signaling mechanisms in the gut V. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol Gastrointest Liver Physiol 2000; 278: G191-96.
80. Husby S, Jensenius JC, Svehag SE. Passage of undegraded dietary antigen into the blood of healthy adults. Further characterization of the kinetics of uptake and the size distribution of the antigen. Scand J Immunol 1986; 24: 447-55.
81. Husby S, Foged N, Host A, Svehag SE. Passage of dietary antigens into the blood of children with coeliac disease. Quantification and size distribution of absorbed antigens. Gut 1987; 28: 1062-72.
82. Swarbrick ET, Stokes CR, Soothill JF. Absorption of antigens after oral immunisation and the simultaneous induction of specific systemic tolerance. Gut 1979; 20: 121-25.
83. Guihot G, Guimbaud R, Bertrand V, Narcy-Lambare B, Couturier D, Duee PH et al. Inducible nitric oxide synthase activity in colon biopsies from inflammatory areas: correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn's disease. Amino Acids 2000; 18: 229-37.
84. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999; 48: 137-43.
85. Yamada Y, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology 1992; 102: 1524-34.
86. Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 1998; 274: G203-09.
87. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270: 1203-07.
88. Youakim A, Ahdieh M. Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am J Physiol 1999; 276: G1279-88.
89. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999; 116: 301-09.
90. Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Malagelada JR. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut 2001; 48: 503-07.
91. Hudault S, Guignot J, Servin AL. Escherichia coli strains colonising the gastrointestinal tract protect germfree mice against Salmonella typhimurium infection. Gut 2001; 49: 47-55.
92. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002; 97: 2000-04.
93. Ainsworth M, Eriksen J, Rasmussen JW, Schaffalitzky de Muckadell OB. Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. Scand J Gastroenterol 1989; 24: 993-98.
94. Howden CW, Gillanders I, Morris AJ, Duncan A, Danesh B, Russell RI. Intestinal permeability in patients with Crohn's disease and their first-degree relatives. Am J Gastroenterol 1994; 89: 1175-76.
95. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, Binder V. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994; 35: 68-72.
96. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986; 105: 883-85.
97. Secondulfo M, de Magistris L, Fiandra R, Caserta L, Belletta M, Tartaglione MT et al. Intestinal permeability in Crohn's disease patients and their first degree relatives. Dig Liver Dis 2001; 33: 680-85.
98. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999; 5: 262-70.
99. Cornet A, Savidge TC, Cabarrocas J, Deng WL, Colombel JF, Lassmann H et al. Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A 2001; 98: 13306-11.
100. Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 1998; 93: 189-201.